Spirit Semiconductor Expanding Theale Headquarters and Opening Second Office in Leeds, UK
Spirit Semiconductor, an innovator in high-performance radio frequency solutions, today announced it will be moving to a new headquarters in Theale, U.K. and will be opening a new satellite office in Leeds, U.K. to tap into the strong radio frequency (RF) monolithic microwave integrated circuit (MMIC) and filter engineering talent in Northern England. The expansion comes on the heels of swift customer adoption and deployment of Spirit Semiconductor’s technology for 5G massive multiple-input and multiple-output (mMIMO) and small cell base stations.
Since the company’s inception in 2020, it has experienced rapid growth, developing a core team of 15 people in less than one year. Located in one of the U.K.’s technology hotbeds, the new office is five times larger than current Spirit headquarters, boasting 9,000 square feet of office space. The new Leeds office will support the company’s plans to expand its product portfolio and enter into other high growth markets.
“When Spirit Semiconductor was founded last year, we were solely focused on creating cutting edge radio frequency products for 5G mMIMO. Currently, our products are being evaluated by customers but the feedback we have received so far has been hugely positive and really provides us with the encouragement we need to branch out into other markets,” said Mark Moffat, managing director of Spirit Semiconductor. “At this rate, we are targeting 65% growth in 2021. This is only the beginning for our company, and I could not be more excited to see what the next year brings by way of innovation and expansion.”
“Massive MIMO architectures change the fundamental building blocks of the RF chain dramatically,” commented Joe Madden, chief analyst at Mobile Experts. “We are experiencing very rapid market growth for some RF components as the base station design adapts to 32T and 64T variations of massive MIMO, with tight performance requirements for RFICs to support a wide range of applications.”
Spirit Semiconductor is looking for the semiconductor industry’s top talent. The company is currently hiring for several positions: principal filter design engineer, principal MMIC design engineer, senior MMIC design engineer and senior analog IC design engineer. For additional information, contact Luke Ord at IC Resources, luke.ord@ic-resources.com, +44 118 907 3070.
“IC Resources is excited to be helping Spirit Semiconductor to identify the right talent to fuel its impressive growth,” commented Kathy Campling, client services director at IC Resources. “Spirit’s strong business plan, exciting product roadmap and generous benefits package are an attractive proposition to potential employees.”
About Spirit Semiconductor Ltd.
Spirit Semiconductor Ltd. is a United Kingdom based company, founded by experts in the radio frequency (RF) semiconductor industry. We are focused on developing high-performance RF products to support the rapid roll out of 5G massive MIMO (mMIMO), small cell base stations and other markets requiring high performance solutions. At Spirit Semiconductor our approach is intelligent innovation, fast implementation and strong team collaboration. We are an aggressive, fast-moving group that is focused on developing compelling products that meet our customers’ needs and timescales, while maintaining a strong team ethic and collaborative spirit. We believe in developing a balanced team that has all levels of experience and fostering an environment where everyone has the opportunity to learn and grow. To learn more, visit www.spiritsemiconductor.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005291/en/
Contact information
Olivia Metcalfe
Townsend Team
olivia@townsendteam.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom